Gen-003 For Genital Herpes

d12_fitc__cy32

There have been no new therapies for genital herpes in 20 years. GEN-003 has consistently and safely improved several important genital herpes disease parameters in clinical studies.

See our latest presented work on genital herpes >>

Personalized Cancer Vaccines

cells

 Genocea understands that cancer is personal. We are leveraging our ATLAS platform to identify new targets that are specific to each individual. Our expertise in vaccinology enables us to turn those targets to personalized cancer vaccines.

See our latest presented work on Cancer >>

Top Talent

Here at Genocea, we are a team that is committed to impoving lives. Check out our career opportunities.

Cool Science

We have partnered with leading organizations worldwide in pursuit of developing medicines that will improve millions of lives.

Life Changing Products

Stay up to date with Genocea through News & Events as well as our activity on the NASDAQ.

Deep pipeline of medicines that matter.

Genocea is focused on the continued clinical development of GEN-003 and on advancing its personalized cancer vaccine program into the clinic. In addition, it has a number of clinical and pre-clinical infectious disease programs available for partnering.

Infectious Disease Programs Available for Partnering1

1Note:Internal development paused; ongoing focus on partnering assets for further development.